After a year of dwindling coffers and repeated layoff rounds, the Southern California biotech firm Viracta Therapeutics has ...
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...
Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...
Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...
Hosted on MSN28d
This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025.Sana Biotechnology (SANA), a clinical-stage ... analyst Vikram Purohit reaffirmed his “Buy” rating for the stock, setting a price target of $9. Purohit highlighted that the encouraging results ...
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences ...
Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...
Learn more about whether Legend Biotech Corporation or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback